Allosteric regulation and inhibition of protein kinases
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The human genome encodes more than 500 different protein kinases: signaling enzymes with tightly regulated activity. Enzymatic activity within the conserved kinase domain is influenced by numerous regulatory inputs including the binding of regulatory domains, substrates, and the effect of post-translational modifications such as autophosphorylation. Integration of these diverse inputs occurs via allosteric sites that relate signals via networks of amino acid residues to the active site and ensures controlled phosphorylation of kinase substrates. Here, we review mechanisms of allosteric regulation of protein kinases and recent advances in the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Asciminib (ABL001), for instance, stands out as a potent and highly selective ABL kinase inhibitor, specifically targeting the myristoyl-binding site of the enzyme.”
From Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development (2025) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650
Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach
Tanaka, Y., Luo, Y., O’Shea, J. J., & Nakayamada, S. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00726-8 · Cited by 501
Lupardus, P. J., Ultsch, M., Wallweber, H., Bir Kohli, P., Johnson, A. R., & Eigenbrot, C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401180111 · Cited by 229
Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation
Burslem, G. M., Schultz, A. R., Bondeson, D. P., Eide, C. A., Savage Stevens, S. L., Druker, B. J., & Crews, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1236 · Cited by 212
Structural basis for the action of the drug trametinib at KSR-bound MEK
Khan, Z. M., Real, A. M., Marsiglia, W. M., Chow, A., Duffy, M. E., Yerabolu, J. R., Scopton, A. P., & Dar, A. C. (2020) · Nature · doi:10.1038/s41586-020-2760-4 · Cited by 178
Rational Engineering of Enzyme Allosteric Regulation through Sequence Evolution Analysis
Yang, J.-S., Seo, S. W., Jang, S., Jung, G. Y., & Kim, S. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002612 · Cited by 87
Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
Majumdar, A., Burban, D. J., Muretta, J. M., Thompson, A. R., Engel, T. A., Rasmussen, D. M., Subrahmanian, M. V., Veglia, G., Thomas, D. D., & Levinson, N. M. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00725-y · Cited by 65
Mingione, V. R., Foda, Z. H., Paung, Y., Philipose, H., Rangwala, A. M., Shan, Y., & Seeliger, M. A. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167628 · Cited by 13
Self-citation
Research works printed but not linked: 64
- 2002, Evolution of protein kinase signaling from yeast to man, Trends Biochem. Sci., 27, 514, 10.1016/s0968-0004(02)02179-5 · DOI · Paper page
- 2012, Evolution of the eukaryotic protein kinases as dynamic molecular switches, Philos. Trans. R. Soc. Lond. B Biol. Sci., 367, 2517, 10.1098/rstb.2012.0054 · DOI · Paper page
- 2011, Protein kinases: evolution of dynamic regulatory proteins, Trends Biochem. Sci., 36, 65, 10.1016/j.tibs.2010.09.006 · DOI · Paper page
- 2015, A dynamically coupled allosteric network underlies binding cooperativity in Src kinase, Nat. Commun., 6, 5939, 10.1038/ncomms6939 · DOI · Paper page
- 2018, The Src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases, Crit. Rev. Biochem. Mol. Biol., 53, 535, 10.1080/10409238.2018.1495173 · DOI · Paper page
- 2003, Structural basis for the autoinhibition of c-Abl tyrosine kinase, Cell, 112, 859, 10.1016/s0092-8674(03)00194-6 · DOI · Paper page
- 2022, Conformational switches that control the TEC kinase - PLCgamma signaling axis, J. Struct. Biol. X, 6, 100061, 10.1016/j.yjsbx.2022.100061 · DOI
- 2013, Ack1: activation and regulation by allostery, PLoS ONE, 8, e53994, 10.1371/journal.pone.0053994 · DOI
- 2004, Role of the Brk SH3 domain in substrate recognition, Oncogene, 23, 2216, 10.1038/sj.onc.1207339 · doi:10.1038/sj.onc.1207339
- 2001, Autoinhibition of mixed lineage kinase 3 through its Src homology 3 domain, J. Biol. Chem., 276, 45598, 10.1074/jbc.M107176200 · DOI
- 2020, Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms, Nat. Commun., 11, 2319, 10.1038/s41467-020-16128-5 · DOI · Paper page
- 2008, Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation, Cell, 134, 793, 10.1016/j.cell.2008.07.047 · DOI · Paper page
- 2005, The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation, Structure, 13, 861, 10.1016/j.str.2005.03.012 · DOI · Paper page
- 2011, The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling, Nat. Struct. Mol. Biol., 18, 971, 10.1038/nsmb.2099 · DOI · Paper page
- 2015, Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2), J. Biol. Chem., 290, 27261, 10.1074/jbc.M115.672048 · DOI
- 2014, Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase, Nat. Struct. Mol. Biol., 21, 579, 10.1038/nsmb.2849 · DOI · Paper page
- 2010, Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases, J. Cell. Mol. Med., 14, 504, 10.1111/j.1582-4934.2010.01018.x · DOI · Paper page
- 2006, The ubiquitin-associated domain of AMPK-related kinases regulates conformation and LKB1-mediated phosphorylation and activation, Biochem. J., 394, 545, 10.1042/BJ20051844 · DOI · Paper page
- 2018, Structural basis for MARK1 kinase autoinhibition by its KA1 domain, Structure, 26, 1137, 10.1016/j.str.2018.05.008 · DOI
- 2009, Structural insight into the autoinhibition mechanism of AMP-activated protein kinase, Nature, 459, 1146, 10.1038/nature08075 · DOI · Paper page
- 2010, Cell signaling by receptor tyrosine kinases, Cell, 141, 1117, 10.1016/j.cell.2010.06.011 · DOI · Paper page
- 2016, Mechanism of FGF receptor dimerization and activation, Nat. Commun., 7, 10262, 10.1038/ncomms10262 · DOI · Paper page
- 2017, Studying the conformation of a receptor tyrosine kinase in solution by inhibitor-based spin labeling, Angew. Chem. Int. Ed. Engl., 56, 8417, 10.1002/anie.201703154 · DOI
- 1993, Crystal structure of cyclin-dependent kinase 2, Nature, 363, 595, 10.1038/363595a0 · DOI · Paper page
- 1995, Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2, Mol. Cell. Biol., 15, 345, 10.1128/MCB.15.1.345 · DOI
- 1995, Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex, Nature, 376, 313, 10.1038/376313a0 · DOI · Paper page
- 2017, Atomic view of the energy landscape in the allosteric regulation of Abl kinase, Nat. Struct. Mol. Biol., 24, 893, 10.1038/nsmb.3470 · DOI · Paper page
- 2016, Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes, Pharmacol. Res., 103, 26, 10.1016/j.phrs.2015.10.021 · DOI · Paper page
- 2019, Allosteric modulator discovery: from serendipity to structure-Based design, J. Med. Chem., 62, 6405, 10.1021/acs.jmedchem.8b01749 · DOI · Paper page
- 2017, Computational tools for allosteric drug discovery: site identification and focus library design, Methods Mol. Biol., 1529, 439, 10.1007/978-1-4939-6637-0_23 · DOI
- 2021, Overcoming therapy resistance in EGFR-mutant lung cancer, Nat. Cancer, 2, 377, 10.1038/s43018-021-00195-8 · DOI · Paper page
- 2016, EGFR c797s mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer, J. Hematol. Oncol., 9, 59, 10.1186/s13045-016-0290-1 · DOI · Paper page
- 2016, Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors, Nature, 534, 129, 10.1038/nature17960 · DOI · Paper page
- 2019, Single and dual targeting of mutant EGFR with an allosteric inhibitor, Cancer Discov., 9, 926, 10.1158/2159-8290.CD-18-0903 · DOI · Paper page
- 2021, Chronic myeloid leukaemia, Lancet, 398, 1914, 10.1016/S0140-6736(21)01204-6 · DOI · Paper page
- 2010, Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors, Nature, 463, 501, 10.1038/nature08675 · DOI · Paper page
- 2017, The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1, Nature, 543, 733, 10.1038/nature21702 · DOI · Paper page
- 2018, Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1, J. Med. Chem., 61, 8120, 10.1021/acs.jmedchem.8b01040 · DOI · Paper page
- 2022, Mechanistic insights into co-administration of allosteric and orthosteric drugs to overcome drug-resistance in T315I BCR-ABL1, Front. Pharmacol., 13, 862504, 10.3389/fphar.2022.862504 · DOI
- 2021, Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor, Cancer Cell, 39, 1404, 10.1016/j.ccell.2021.08.009 · DOI · Paper page
- 2011, Discovery of a potential allosteric ligand binding site in CDK2, ACS Chem. Biol., 6, 492, 10.1021/cb100410m · DOI · Paper page
- 2020, Cooperativity between orthosteric inhibitors and allosteric inhibitor 8-anilino-1-naphthalene sulfonic acid (ANS) in cyclin-dependent kinase 2, ACS Chem. Biol., 15, 1759, 10.1021/acschembio.0c00169 · DOI
- 2012, A novel approach to the discovery of small-molecule ligands of CDK2, Chembiochem, 13, 2128, 10.1002/cbic.201200316 · DOI · Paper page
- 2019, Targeting AKT for cancer therapy, Expert Opin. Investig. Drugs., 28, 977, 10.1080/13543784.2019.1676726 · DOI · Paper page
- 2009, Inhibitor hijacking of Akt activation, Nat. Chem. Biol., 5, 484, 10.1038/nchembio.183 · DOI · Paper page
- 2010, MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo, Mol. Cancer Ther., 9, 1956, 10.1158/1535-7163.MCT-09-1012 · DOI · Paper page
- 2016, Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): an orally bioavailable, selective, and potent allosteric AKT inhibitor, J. Med. Chem., 59, 6455, 10.1021/acs.jmedchem.6b00619 · DOI · Paper page
- 2005, Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors, Bioorg. Med. Chem. Lett., 15, 761, 10.1016/j.bmcl.2004.11.011 · DOI · Paper page
- 2021, Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise, Inflamm. Bowel Dis., 27, 2023, 10.1093/ibd/izab135 · DOI · Paper page
- 2014, Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases, J. Med. Chem., 57, 5023, 10.1021/jm401490p · DOI · Paper page
- 2021, Current and future status of JAK inhibitors, Lancet, 398, 803, 10.1016/S0140-6736(21)00438-4 · DOI · Paper page
- 2022, Oral surveillance and JAK inhibitor safety: the theory of relativity, Nat. Rev. Rheumatol., 18, 301, 10.1038/s41584-022-00767-7 · DOI · Paper page
- 2019, Identification of N-methyl nicotinamide and N-methyl pyridazine-3-carboxamide pseudokinase domain ligands as highly selective allosteric inhibitors of tyrosine kinase 2 (TYK2), J. Med. Chem., 62, 8953, 10.1021/acs.jmedchem.9b00443 · DOI
- 2019, Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165, J. Med. Chem., 62, 8973, 10.1021/acs.jmedchem.9b00444 · DOI · Paper page
- 2014, A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1, Proc. Natl Acad. Sci. U.S.A., 111, 18590, 10.1073/pnas.1415365112 · DOI · Paper page
- 2015, Unfolded protein response in cancer: IRE1alpha inhibition by selective kinase ligands does not impair tumor cell viability, ACS Med. Chem. Lett., 6, 68, 10.1021/ml500315b · DOI · Paper page
- 2022, Development of selective phosphatidylinositol 5-phosphate 4-kinase gamma inhibitors with a Non-ATP-competitive, allosteric binding mode, J. Med. Chem., 65, 3359, 10.1021/acs.jmedchem.1c01819 · DOI
- 2022, GCN2 kinase activation by ATP-competitive kinase inhibitors, Nat. Chem. Biol., 18, 207, 10.1038/s41589-021-00947-8 · DOI
- 2015, Novel selection methods for DNA-encoded chemical libraries, Curr. Opin. Chem. Biol., 26, 55, 10.1016/j.cbpa.2015.02.010 · DOI · Paper page
- 2013, Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening, J. Med. Chem., 56, 2738, 10.1021/jm301271j · DOI · Paper page
- 2021, X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease, Science, 372, 642, 10.1126/science.abf7945 · DOI · Paper page
- 2016, Computational approaches to investigating allostery, Curr. Opin. Struct. Biol., 41, 159, 10.1016/j.sbi.2016.06.017 · DOI
- 2009, Dissecting an allosteric switch in caspase-7 using chemical and mutational probes, J. Biol. Chem., 284, 26063, 10.1074/jbc.M109.001826 · doi:10.1074/jbc.m109.001826
- 2022, The protein kinase CK1: inhibition, activation, and possible allosteric modulation, Front. Mol. Biosci., 9, 916232, 10.3389/fmolb.2022.916232 · DOI
Cited by
Breaking the conformational ensemble barrier: Ensemble structure modeling challenges in CASP15
Kryshtafovych, A., Montelione, G., Rigden, D., Mesdaghi, S., Karaca, E., & Moult, J. (2023) · doi:10.22541/au.169199504.48580490/v1 · Cited by 31
Breaking the conformational ensemble barrier: Ensemble structure modeling challenges in CASP15
Kryshtafovych, A., Montelione, G. T., Rigden, D. J., Mesdaghi, S., Karaca, E., & Moult, J. (2023) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.26584 · Cited by 31
Estevam, G. O., Linossi, E., Rao, J., Macdonald, C. B., Ravikumar, A., Chrispens, K. M., Capra, J. A., Coyote-Maestas, W., Pimentel, H., Collisson, E. A., et al. (2025) · eLife · doi:10.7554/elife.101882 · Cited by 17
Estevam, G. O., Linossi, E., Rao, J., Macdonald, C. B., Ravikumar, A., Chrispens, K. M., Capra, J. A., Coyote-Maestas, W., Pimentel, H., Collisson, E. A., et al. (2025) · eLife · doi:10.7554/elife.101882.3 · Cited by 6
Allosteric binding cooperativity in kinases signaling, signalopathies, and drug development
Olivieri, C., Wu, J., Taylor, S. S., & Veglia, G. (2025) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2025.103169 · Cited by 1
Metadata
- Authors
- Mingione, V. R., Paung, Y., Outhwaite, I. R., & Seeliger, M. A.
- Affiliations
- Department of Pharmacological Sciences, Stony Brook University, Stony Brook, NY 11794, U.S.A.
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2023-02-16
- Volume
- 51
- Issue
- 1
- Pages
- 373-385
- ISSN
- 0300-5127
- 1470-8752
- Cited by
- 51
- References
- 8
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allosteric regulation and inhibition of protein kinases. https://app.cochat.ai/papers/10.1042/bst20220940
- The paper
- Mingione, V. R., Paung, Y., Outhwaite, I. R., & Seeliger, M. A. (2023). Allosteric regulation and inhibition of protein kinases. Biochemical Society Transactions. https://doi.org/10.1042/bst20220940
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.